nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT2B7—Epirubicin—bone cancer	0.555	0.816	CbGbCtD
Tapentadol—CYP2C9—Cisplatin—bone cancer	0.0778	0.114	CbGbCtD
Tapentadol—CYP2D6—Doxorubicin—bone cancer	0.0477	0.07	CbGbCtD
Tapentadol—UGT2B7—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00617	0.0606	CbGpPWpGaD
Tapentadol—Rivastigmine—CYP3A4—bone cancer	0.00593	1	CrCbGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—FEV—bone cancer	0.00457	0.0449	CbGpPWpGaD
Tapentadol—UGT2B7—Estrogen metabolism—CYP3A4—bone cancer	0.00323	0.0317	CbGpPWpGaD
Tapentadol—UGT1A9—Irinotecan Pathway—CYP3A4—bone cancer	0.00321	0.0315	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—FEV—bone cancer	0.00286	0.028	CbGpPWpGaD
Tapentadol—UGT2B7—Tamoxifen metabolism—CYP3A4—bone cancer	0.00285	0.028	CbGpPWpGaD
Tapentadol—UGT2B7—Metapathway biotransformation—CYP4V2—bone cancer	0.00265	0.026	CbGpPWpGaD
Tapentadol—UGT1A9—Estrogen metabolism—CYP3A4—bone cancer	0.00262	0.0257	CbGpPWpGaD
Tapentadol—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00235	0.023	CbGpPWpGaD
Tapentadol—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00217	0.0213	CbGpPWpGaD
Tapentadol—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00216	0.0212	CbGpPWpGaD
Tapentadol—UGT1A9—Metapathway biotransformation—CYP4V2—bone cancer	0.00215	0.0211	CbGpPWpGaD
Tapentadol—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00214	0.021	CbGpPWpGaD
Tapentadol—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00205	0.0201	CbGpPWpGaD
Tapentadol—UGT1A9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00166	0.0162	CbGpPWpGaD
Tapentadol—OPRK1—Mecp2 and Associated Rett Syndrome—EZH2—bone cancer	0.00152	0.0149	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—TNFRSF11A—bone cancer	0.0015	0.0147	CbGpPWpGaD
Tapentadol—Thinking abnormal—Doxorubicin—bone cancer	0.00148	0.00699	CcSEcCtD
Tapentadol—Bradycardia—Cisplatin—bone cancer	0.00145	0.00688	CcSEcCtD
Tapentadol—Abnormal dreams—Epirubicin—bone cancer	0.00144	0.00683	CcSEcCtD
Tapentadol—Dysarthria—Doxorubicin—bone cancer	0.00143	0.00676	CcSEcCtD
Tapentadol—Urinary tract disorder—Cisplatin—bone cancer	0.00141	0.00668	CcSEcCtD
Tapentadol—Connective tissue disorder—Cisplatin—bone cancer	0.0014	0.00664	CcSEcCtD
Tapentadol—Urethral disorder—Cisplatin—bone cancer	0.0014	0.00663	CcSEcCtD
Tapentadol—Visual impairment—Cisplatin—bone cancer	0.00138	0.00652	CcSEcCtD
Tapentadol—Coordination abnormal—Doxorubicin—bone cancer	0.00138	0.00651	CcSEcCtD
Tapentadol—Abnormal dreams—Doxorubicin—bone cancer	0.00134	0.00632	CcSEcCtD
Tapentadol—Eye disorder—Cisplatin—bone cancer	0.00134	0.00632	CcSEcCtD
Tapentadol—Cardiac disorder—Cisplatin—bone cancer	0.00133	0.00627	CcSEcCtD
Tapentadol—Immune system disorder—Cisplatin—bone cancer	0.00129	0.00611	CcSEcCtD
Tapentadol—Mediastinal disorder—Cisplatin—bone cancer	0.00129	0.00609	CcSEcCtD
Tapentadol—Mental disability—Epirubicin—bone cancer	0.00127	0.006	CcSEcCtD
Tapentadol—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00125	0.0122	CbGpPWpGaD
Tapentadol—Malnutrition—Cisplatin—bone cancer	0.00124	0.00589	CcSEcCtD
Tapentadol—UGT1A9—PPAR Alpha Pathway—CDK4—bone cancer	0.00121	0.0119	CbGpPWpGaD
Tapentadol—Visual disturbance—Methotrexate—bone cancer	0.0012	0.00566	CcSEcCtD
Tapentadol—Mental disability—Doxorubicin—bone cancer	0.00117	0.00555	CcSEcCtD
Tapentadol—Vision blurred—Cisplatin—bone cancer	0.00117	0.00555	CcSEcCtD
Tapentadol—Tremor—Cisplatin—bone cancer	0.00117	0.00551	CcSEcCtD
Tapentadol—Lethargy—Methotrexate—bone cancer	0.00116	0.00547	CcSEcCtD
Tapentadol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00116	0.0114	CbGpPWpGaD
Tapentadol—Hot flush—Epirubicin—bone cancer	0.00113	0.00536	CcSEcCtD
Tapentadol—Osteoarthritis—Methotrexate—bone cancer	0.00113	0.00536	CcSEcCtD
Tapentadol—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.00113	0.0111	CbGpPWpGaD
Tapentadol—Menopausal symptoms—Epirubicin—bone cancer	0.00112	0.00532	CcSEcCtD
Tapentadol—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.00109	0.0107	CbGpPWpGaD
Tapentadol—Lethargy—Epirubicin—bone cancer	0.00108	0.00512	CcSEcCtD
Tapentadol—Irritability—Methotrexate—bone cancer	0.00108	0.00512	CcSEcCtD
Tapentadol—Convulsion—Cisplatin—bone cancer	0.00108	0.0051	CcSEcCtD
Tapentadol—Ataxia—Methotrexate—bone cancer	0.00107	0.00504	CcSEcCtD
Tapentadol—Osteoarthritis—Epirubicin—bone cancer	0.00106	0.00502	CcSEcCtD
Tapentadol—Anxiety—Cisplatin—bone cancer	0.00106	0.00499	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00105	0.00498	CcSEcCtD
Tapentadol—Hot flush—Doxorubicin—bone cancer	0.00105	0.00496	CcSEcCtD
Tapentadol—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.00104	0.0102	CbGpPWpGaD
Tapentadol—Menopausal symptoms—Doxorubicin—bone cancer	0.00104	0.00492	CcSEcCtD
Tapentadol—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00103	0.0101	CbGpPWpGaD
Tapentadol—Breast disorder—Methotrexate—bone cancer	0.00102	0.00485	CcSEcCtD
Tapentadol—Oedema—Cisplatin—bone cancer	0.00102	0.0048	CcSEcCtD
Tapentadol—Anaphylactic shock—Cisplatin—bone cancer	0.00102	0.0048	CcSEcCtD
Tapentadol—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.00101	0.00992	CbGpPWpGaD
Tapentadol—Infection—Cisplatin—bone cancer	0.00101	0.00477	CcSEcCtD
Tapentadol—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.001	0.00983	CbGpPWpGaD
Tapentadol—Lethargy—Doxorubicin—bone cancer	0.001	0.00474	CcSEcCtD
Tapentadol—Ataxia—Epirubicin—bone cancer	0.000997	0.00472	CcSEcCtD
Tapentadol—Nervous system disorder—Cisplatin—bone cancer	0.000996	0.00471	CcSEcCtD
Tapentadol—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000993	0.00975	CbGpPWpGaD
Tapentadol—Tachycardia—Cisplatin—bone cancer	0.000991	0.00469	CcSEcCtD
Tapentadol—Skin disorder—Cisplatin—bone cancer	0.000986	0.00467	CcSEcCtD
Tapentadol—Osteoarthritis—Doxorubicin—bone cancer	0.000982	0.00464	CcSEcCtD
Tapentadol—Hyperhidrosis—Cisplatin—bone cancer	0.000982	0.00464	CcSEcCtD
Tapentadol—Breast disorder—Epirubicin—bone cancer	0.000959	0.00454	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000955	0.00452	CcSEcCtD
Tapentadol—Hypotension—Cisplatin—bone cancer	0.000949	0.00449	CcSEcCtD
Tapentadol—Nasopharyngitis—Epirubicin—bone cancer	0.000949	0.00449	CcSEcCtD
Tapentadol—Abdominal discomfort—Methotrexate—bone cancer	0.000939	0.00444	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000936	0.00443	CcSEcCtD
Tapentadol—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000929	0.00912	CbGpPWpGaD
Tapentadol—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000925	0.00438	CcSEcCtD
Tapentadol—Ataxia—Doxorubicin—bone cancer	0.000923	0.00437	CcSEcCtD
Tapentadol—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000921	0.00904	CbGpPWpGaD
Tapentadol—Paraesthesia—Cisplatin—bone cancer	0.000912	0.00431	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Methotrexate—bone cancer	0.000911	0.00431	CcSEcCtD
Tapentadol—Dyspnoea—Cisplatin—bone cancer	0.000905	0.00428	CcSEcCtD
Tapentadol—Erectile dysfunction—Methotrexate—bone cancer	0.000902	0.00427	CcSEcCtD
Tapentadol—Breast disorder—Doxorubicin—bone cancer	0.000887	0.0042	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000884	0.00418	CcSEcCtD
Tapentadol—Decreased appetite—Cisplatin—bone cancer	0.000883	0.00418	CcSEcCtD
Tapentadol—Nasopharyngitis—Doxorubicin—bone cancer	0.000878	0.00415	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Cisplatin—bone cancer	0.000877	0.00415	CcSEcCtD
Tapentadol—OPRD1—G alpha (i) signalling events—RGS1—bone cancer	0.000875	0.00858	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—GRM4—bone cancer	0.000875	0.00858	CbGpPWpGaD
Tapentadol—Infestation—Methotrexate—bone cancer	0.000874	0.00413	CcSEcCtD
Tapentadol—Infestation NOS—Methotrexate—bone cancer	0.000874	0.00413	CcSEcCtD
Tapentadol—Depression—Methotrexate—bone cancer	0.000871	0.00412	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000866	0.0041	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Epirubicin—bone cancer	0.000852	0.00403	CcSEcCtD
Tapentadol—Pollakiuria—Epirubicin—bone cancer	0.000847	0.00401	CcSEcCtD
Tapentadol—Feeling abnormal—Cisplatin—bone cancer	0.000837	0.00396	CcSEcCtD
Tapentadol—Weight decreased—Epirubicin—bone cancer	0.00083	0.00392	CcSEcCtD
Tapentadol—Infestation NOS—Epirubicin—bone cancer	0.000818	0.00387	CcSEcCtD
Tapentadol—Infestation—Epirubicin—bone cancer	0.000818	0.00387	CcSEcCtD
Tapentadol—Urinary tract infection—Epirubicin—bone cancer	0.000795	0.00376	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000788	0.00373	CcSEcCtD
Tapentadol—Pollakiuria—Doxorubicin—bone cancer	0.000784	0.00371	CcSEcCtD
Tapentadol—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000778	0.00763	CbGpPWpGaD
Tapentadol—UGT2B7—Phase II conjugation—GSTP1—bone cancer	0.000775	0.00761	CbGpPWpGaD
Tapentadol—Urinary tract disorder—Methotrexate—bone cancer	0.000774	0.00366	CcSEcCtD
Tapentadol—Urethral disorder—Methotrexate—bone cancer	0.000769	0.00364	CcSEcCtD
Tapentadol—Weight decreased—Doxorubicin—bone cancer	0.000768	0.00363	CcSEcCtD
Tapentadol—OPRK1—G alpha (i) signalling events—GRM4—bone cancer	0.000767	0.00753	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—RGS1—bone cancer	0.000767	0.00753	CbGpPWpGaD
Tapentadol—Infestation NOS—Doxorubicin—bone cancer	0.000756	0.00358	CcSEcCtD
Tapentadol—Infestation—Doxorubicin—bone cancer	0.000756	0.00358	CcSEcCtD
Tapentadol—Visual impairment—Methotrexate—bone cancer	0.000756	0.00358	CcSEcCtD
Tapentadol—Hypersensitivity—Cisplatin—bone cancer	0.000748	0.00354	CcSEcCtD
Tapentadol—Bradycardia—Epirubicin—bone cancer	0.000747	0.00353	CcSEcCtD
Tapentadol—Urinary tract infection—Doxorubicin—bone cancer	0.000735	0.00348	CcSEcCtD
Tapentadol—Eye disorder—Methotrexate—bone cancer	0.000733	0.00347	CcSEcCtD
Tapentadol—Hypoaesthesia—Epirubicin—bone cancer	0.00073	0.00345	CcSEcCtD
Tapentadol—Asthenia—Cisplatin—bone cancer	0.000728	0.00345	CcSEcCtD
Tapentadol—Cardiac disorder—Methotrexate—bone cancer	0.000728	0.00344	CcSEcCtD
Tapentadol—Urinary tract disorder—Epirubicin—bone cancer	0.000725	0.00343	CcSEcCtD
Tapentadol—Connective tissue disorder—Epirubicin—bone cancer	0.000721	0.00341	CcSEcCtD
Tapentadol—Urethral disorder—Epirubicin—bone cancer	0.000719	0.0034	CcSEcCtD
Tapentadol—Angiopathy—Methotrexate—bone cancer	0.000711	0.00337	CcSEcCtD
Tapentadol—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000709	0.00696	CbGpPWpGaD
Tapentadol—Immune system disorder—Methotrexate—bone cancer	0.000708	0.00335	CcSEcCtD
Tapentadol—Visual impairment—Epirubicin—bone cancer	0.000707	0.00335	CcSEcCtD
Tapentadol—Mediastinal disorder—Methotrexate—bone cancer	0.000707	0.00334	CcSEcCtD
Tapentadol—Chills—Methotrexate—bone cancer	0.000704	0.00333	CcSEcCtD
Tapentadol—Diarrhoea—Cisplatin—bone cancer	0.000695	0.00329	CcSEcCtD
Tapentadol—Bradycardia—Doxorubicin—bone cancer	0.000691	0.00327	CcSEcCtD
Tapentadol—Mental disorder—Methotrexate—bone cancer	0.000687	0.00325	CcSEcCtD
Tapentadol—Eye disorder—Epirubicin—bone cancer	0.000686	0.00324	CcSEcCtD
Tapentadol—Malnutrition—Methotrexate—bone cancer	0.000683	0.00323	CcSEcCtD
Tapentadol—Cardiac disorder—Epirubicin—bone cancer	0.000681	0.00322	CcSEcCtD
Tapentadol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000676	0.00663	CbGpPWpGaD
Tapentadol—Hypoaesthesia—Doxorubicin—bone cancer	0.000676	0.0032	CcSEcCtD
Tapentadol—Urinary tract disorder—Doxorubicin—bone cancer	0.000671	0.00317	CcSEcCtD
Tapentadol—Connective tissue disorder—Doxorubicin—bone cancer	0.000667	0.00316	CcSEcCtD
Tapentadol—Angiopathy—Epirubicin—bone cancer	0.000666	0.00315	CcSEcCtD
Tapentadol—Urethral disorder—Doxorubicin—bone cancer	0.000666	0.00315	CcSEcCtD
Tapentadol—Immune system disorder—Epirubicin—bone cancer	0.000663	0.00314	CcSEcCtD
Tapentadol—Mediastinal disorder—Epirubicin—bone cancer	0.000661	0.00313	CcSEcCtD
Tapentadol—Chills—Epirubicin—bone cancer	0.000658	0.00312	CcSEcCtD
Tapentadol—Visual impairment—Doxorubicin—bone cancer	0.000654	0.0031	CcSEcCtD
Tapentadol—OPRM1—G alpha (i) signalling events—GRM4—bone cancer	0.000648	0.00636	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—RGS1—bone cancer	0.000648	0.00636	CbGpPWpGaD
Tapentadol—Vomiting—Cisplatin—bone cancer	0.000646	0.00305	CcSEcCtD
Tapentadol—Vision blurred—Methotrexate—bone cancer	0.000643	0.00304	CcSEcCtD
Tapentadol—Mental disorder—Epirubicin—bone cancer	0.000643	0.00304	CcSEcCtD
Tapentadol—HTR3A—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000641	0.0063	CbGpPWpGaD
Tapentadol—Rash—Cisplatin—bone cancer	0.00064	0.00303	CcSEcCtD
Tapentadol—Dermatitis—Cisplatin—bone cancer	0.00064	0.00303	CcSEcCtD
Tapentadol—Malnutrition—Epirubicin—bone cancer	0.000639	0.00302	CcSEcCtD
Tapentadol—Eye disorder—Doxorubicin—bone cancer	0.000635	0.003	CcSEcCtD
Tapentadol—Cardiac disorder—Doxorubicin—bone cancer	0.00063	0.00298	CcSEcCtD
Tapentadol—UGT1A9—Phase II conjugation—GSTP1—bone cancer	0.00063	0.00618	CbGpPWpGaD
Tapentadol—Tension—Epirubicin—bone cancer	0.000627	0.00297	CcSEcCtD
Tapentadol—Nervousness—Epirubicin—bone cancer	0.00062	0.00294	CcSEcCtD
Tapentadol—Angiopathy—Doxorubicin—bone cancer	0.000616	0.00291	CcSEcCtD
Tapentadol—Immune system disorder—Doxorubicin—bone cancer	0.000613	0.0029	CcSEcCtD
Tapentadol—Vertigo—Methotrexate—bone cancer	0.000613	0.0029	CcSEcCtD
Tapentadol—Mediastinal disorder—Doxorubicin—bone cancer	0.000612	0.0029	CcSEcCtD
Tapentadol—Chills—Doxorubicin—bone cancer	0.000609	0.00288	CcSEcCtD
Tapentadol—Nausea—Cisplatin—bone cancer	0.000603	0.00285	CcSEcCtD
Tapentadol—Vision blurred—Epirubicin—bone cancer	0.000602	0.00285	CcSEcCtD
Tapentadol—Cough—Methotrexate—bone cancer	0.000596	0.00282	CcSEcCtD
Tapentadol—Mental disorder—Doxorubicin—bone cancer	0.000595	0.00281	CcSEcCtD
Tapentadol—Convulsion—Methotrexate—bone cancer	0.000591	0.0028	CcSEcCtD
Tapentadol—Malnutrition—Doxorubicin—bone cancer	0.000591	0.0028	CcSEcCtD
Tapentadol—Agitation—Epirubicin—bone cancer	0.000587	0.00278	CcSEcCtD
Tapentadol—Arthralgia—Methotrexate—bone cancer	0.000581	0.00275	CcSEcCtD
Tapentadol—Tension—Doxorubicin—bone cancer	0.00058	0.00274	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000577	0.00273	CcSEcCtD
Tapentadol—Nervousness—Doxorubicin—bone cancer	0.000574	0.00272	CcSEcCtD
Tapentadol—Vertigo—Epirubicin—bone cancer	0.000574	0.00272	CcSEcCtD
Tapentadol—Syncope—Epirubicin—bone cancer	0.000573	0.00271	CcSEcCtD
Tapentadol—Palpitations—Epirubicin—bone cancer	0.000565	0.00267	CcSEcCtD
Tapentadol—Confusional state—Methotrexate—bone cancer	0.000562	0.00266	CcSEcCtD
Tapentadol—Loss of consciousness—Epirubicin—bone cancer	0.000561	0.00266	CcSEcCtD
Tapentadol—Cough—Epirubicin—bone cancer	0.000557	0.00264	CcSEcCtD
Tapentadol—Anaphylactic shock—Methotrexate—bone cancer	0.000557	0.00264	CcSEcCtD
Tapentadol—Vision blurred—Doxorubicin—bone cancer	0.000557	0.00264	CcSEcCtD
Tapentadol—HTR3A—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000554	0.00543	CbGpPWpGaD
Tapentadol—Convulsion—Epirubicin—bone cancer	0.000554	0.00262	CcSEcCtD
Tapentadol—Infection—Methotrexate—bone cancer	0.000553	0.00262	CcSEcCtD
Tapentadol—Nervous system disorder—Methotrexate—bone cancer	0.000546	0.00258	CcSEcCtD
Tapentadol—Arthralgia—Epirubicin—bone cancer	0.000544	0.00257	CcSEcCtD
Tapentadol—Agitation—Doxorubicin—bone cancer	0.000543	0.00257	CcSEcCtD
Tapentadol—Anxiety—Epirubicin—bone cancer	0.000542	0.00256	CcSEcCtD
Tapentadol—Skin disorder—Methotrexate—bone cancer	0.000541	0.00256	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00054	0.00256	CcSEcCtD
Tapentadol—Hyperhidrosis—Methotrexate—bone cancer	0.000539	0.00255	CcSEcCtD
Tapentadol—Dry mouth—Epirubicin—bone cancer	0.000532	0.00252	CcSEcCtD
Tapentadol—Vertigo—Doxorubicin—bone cancer	0.000531	0.00251	CcSEcCtD
Tapentadol—UGT2B7—Biological oxidations—CYP3A4—bone cancer	0.00053	0.00521	CbGpPWpGaD
Tapentadol—Syncope—Doxorubicin—bone cancer	0.00053	0.00251	CcSEcCtD
Tapentadol—OPRD1—GPCR ligand binding—GRM4—bone cancer	0.00053	0.0052	CbGpPWpGaD
Tapentadol—Confusional state—Epirubicin—bone cancer	0.000526	0.00249	CcSEcCtD
Tapentadol—UGT2B7—Metapathway biotransformation—CYP3A4—bone cancer	0.000523	0.00513	CbGpPWpGaD
Tapentadol—Palpitations—Doxorubicin—bone cancer	0.000522	0.00247	CcSEcCtD
Tapentadol—Oedema—Epirubicin—bone cancer	0.000521	0.00247	CcSEcCtD
Tapentadol—Anaphylactic shock—Epirubicin—bone cancer	0.000521	0.00247	CcSEcCtD
Tapentadol—Hypotension—Methotrexate—bone cancer	0.000521	0.00246	CcSEcCtD
Tapentadol—Loss of consciousness—Doxorubicin—bone cancer	0.00052	0.00246	CcSEcCtD
Tapentadol—Infection—Epirubicin—bone cancer	0.000518	0.00245	CcSEcCtD
Tapentadol—UGT2B7—NRF2 pathway—GSTP1—bone cancer	0.000517	0.00508	CbGpPWpGaD
Tapentadol—UGT2B7—NRF2 pathway—TGFBR2—bone cancer	0.000517	0.00508	CbGpPWpGaD
Tapentadol—Cough—Doxorubicin—bone cancer	0.000516	0.00244	CcSEcCtD
Tapentadol—Shock—Epirubicin—bone cancer	0.000513	0.00243	CcSEcCtD
Tapentadol—Convulsion—Doxorubicin—bone cancer	0.000512	0.00242	CcSEcCtD
Tapentadol—Nervous system disorder—Epirubicin—bone cancer	0.000511	0.00242	CcSEcCtD
Tapentadol—SLC6A4—NRF2 pathway—GSTP1—bone cancer	0.000509	0.005	CbGpPWpGaD
Tapentadol—SLC6A4—NRF2 pathway—TGFBR2—bone cancer	0.000509	0.005	CbGpPWpGaD
Tapentadol—Tachycardia—Epirubicin—bone cancer	0.000509	0.00241	CcSEcCtD
Tapentadol—SLC6A4—Circadian rythm related genes—GNA11—bone cancer	0.000508	0.00499	CbGpPWpGaD
Tapentadol—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000508	0.0024	CcSEcCtD
Tapentadol—Skin disorder—Epirubicin—bone cancer	0.000506	0.0024	CcSEcCtD
Tapentadol—SLC6A4—Circadian rythm related genes—EZH2—bone cancer	0.000506	0.00497	CbGpPWpGaD
Tapentadol—Hyperhidrosis—Epirubicin—bone cancer	0.000504	0.00238	CcSEcCtD
Tapentadol—Insomnia—Methotrexate—bone cancer	0.000504	0.00238	CcSEcCtD
Tapentadol—Arthralgia—Doxorubicin—bone cancer	0.000503	0.00238	CcSEcCtD
Tapentadol—Anxiety—Doxorubicin—bone cancer	0.000502	0.00237	CcSEcCtD
Tapentadol—Paraesthesia—Methotrexate—bone cancer	0.0005	0.00237	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.0005	0.00236	CcSEcCtD
Tapentadol—Dyspnoea—Methotrexate—bone cancer	0.000497	0.00235	CcSEcCtD
Tapentadol—Somnolence—Methotrexate—bone cancer	0.000495	0.00234	CcSEcCtD
Tapentadol—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000495	0.00485	CbGpPWpGaD
Tapentadol—Dry mouth—Doxorubicin—bone cancer	0.000492	0.00233	CcSEcCtD
Tapentadol—Dyspepsia—Methotrexate—bone cancer	0.00049	0.00232	CcSEcCtD
Tapentadol—Hypotension—Epirubicin—bone cancer	0.000487	0.0023	CcSEcCtD
Tapentadol—Confusional state—Doxorubicin—bone cancer	0.000486	0.0023	CcSEcCtD
Tapentadol—Decreased appetite—Methotrexate—bone cancer	0.000484	0.00229	CcSEcCtD
Tapentadol—Oedema—Doxorubicin—bone cancer	0.000482	0.00228	CcSEcCtD
Tapentadol—Anaphylactic shock—Doxorubicin—bone cancer	0.000482	0.00228	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Methotrexate—bone cancer	0.000481	0.00228	CcSEcCtD
Tapentadol—Fatigue—Methotrexate—bone cancer	0.00048	0.00227	CcSEcCtD
Tapentadol—Infection—Doxorubicin—bone cancer	0.000479	0.00227	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000475	0.00225	CcSEcCtD
Tapentadol—Shock—Doxorubicin—bone cancer	0.000475	0.00225	CcSEcCtD
Tapentadol—Nervous system disorder—Doxorubicin—bone cancer	0.000473	0.00224	CcSEcCtD
Tapentadol—Insomnia—Epirubicin—bone cancer	0.000472	0.00223	CcSEcCtD
Tapentadol—Tachycardia—Doxorubicin—bone cancer	0.000471	0.00223	CcSEcCtD
Tapentadol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00047	0.00462	CbGpPWpGaD
Tapentadol—Skin disorder—Doxorubicin—bone cancer	0.000469	0.00222	CcSEcCtD
Tapentadol—Paraesthesia—Epirubicin—bone cancer	0.000468	0.00221	CcSEcCtD
Tapentadol—Hyperhidrosis—Doxorubicin—bone cancer	0.000466	0.00221	CcSEcCtD
Tapentadol—Dyspnoea—Epirubicin—bone cancer	0.000465	0.0022	CcSEcCtD
Tapentadol—OPRK1—GPCR ligand binding—GRM4—bone cancer	0.000464	0.00456	CbGpPWpGaD
Tapentadol—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000464	0.00456	CbGpPWpGaD
Tapentadol—Somnolence—Epirubicin—bone cancer	0.000464	0.00219	CcSEcCtD
Tapentadol—OPRD1—GPCR ligand binding—GRM1—bone cancer	0.000459	0.00451	CbGpPWpGaD
Tapentadol—Feeling abnormal—Methotrexate—bone cancer	0.000459	0.00217	CcSEcCtD
Tapentadol—Dyspepsia—Epirubicin—bone cancer	0.000459	0.00217	CcSEcCtD
Tapentadol—UGT2B7—Biological oxidations—GSTP1—bone cancer	0.000454	0.00445	CbGpPWpGaD
Tapentadol—Decreased appetite—Epirubicin—bone cancer	0.000453	0.00214	CcSEcCtD
Tapentadol—Hypotension—Doxorubicin—bone cancer	0.000451	0.00213	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Epirubicin—bone cancer	0.00045	0.00213	CcSEcCtD
Tapentadol—Fatigue—Epirubicin—bone cancer	0.00045	0.00213	CcSEcCtD
Tapentadol—UGT2B7—Metapathway biotransformation—GSTP1—bone cancer	0.000447	0.00439	CbGpPWpGaD
Tapentadol—Constipation—Epirubicin—bone cancer	0.000446	0.00211	CcSEcCtD
Tapentadol—Urticaria—Methotrexate—bone cancer	0.000443	0.00209	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00044	0.00208	CcSEcCtD
Tapentadol—SLC6A2—NRF2 pathway—TGFBR2—bone cancer	0.000438	0.0043	CbGpPWpGaD
Tapentadol—SLC6A2—NRF2 pathway—GSTP1—bone cancer	0.000438	0.0043	CbGpPWpGaD
Tapentadol—Insomnia—Doxorubicin—bone cancer	0.000436	0.00206	CcSEcCtD
Tapentadol—Paraesthesia—Doxorubicin—bone cancer	0.000433	0.00205	CcSEcCtD
Tapentadol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000433	0.00425	CbGpPWpGaD
Tapentadol—UGT1A9—Biological oxidations—CYP3A4—bone cancer	0.000431	0.00423	CbGpPWpGaD
Tapentadol—Dyspnoea—Doxorubicin—bone cancer	0.00043	0.00203	CcSEcCtD
Tapentadol—Feeling abnormal—Epirubicin—bone cancer	0.00043	0.00203	CcSEcCtD
Tapentadol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000429	0.00421	CbGpPWpGaD
Tapentadol—Somnolence—Doxorubicin—bone cancer	0.000429	0.00203	CcSEcCtD
Tapentadol—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000427	0.00419	CbGpPWpGaD
Tapentadol—UGT1A9—Metapathway biotransformation—CYP3A4—bone cancer	0.000425	0.00417	CbGpPWpGaD
Tapentadol—Dyspepsia—Doxorubicin—bone cancer	0.000425	0.00201	CcSEcCtD
Tapentadol—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000423	0.00415	CbGpPWpGaD
Tapentadol—UGT1A9—NRF2 pathway—TGFBR2—bone cancer	0.00042	0.00412	CbGpPWpGaD
Tapentadol—UGT1A9—NRF2 pathway—GSTP1—bone cancer	0.00042	0.00412	CbGpPWpGaD
Tapentadol—Decreased appetite—Doxorubicin—bone cancer	0.000419	0.00198	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000416	0.00197	CcSEcCtD
Tapentadol—Fatigue—Doxorubicin—bone cancer	0.000416	0.00197	CcSEcCtD
Tapentadol—Urticaria—Epirubicin—bone cancer	0.000414	0.00196	CcSEcCtD
Tapentadol—Constipation—Doxorubicin—bone cancer	0.000413	0.00195	CcSEcCtD
Tapentadol—Hypersensitivity—Methotrexate—bone cancer	0.00041	0.00194	CcSEcCtD
Tapentadol—OPRK1—GPCR ligand binding—GRM1—bone cancer	0.000403	0.00395	CbGpPWpGaD
Tapentadol—Asthenia—Methotrexate—bone cancer	0.0004	0.00189	CcSEcCtD
Tapentadol—Feeling abnormal—Doxorubicin—bone cancer	0.000398	0.00188	CcSEcCtD
Tapentadol—Pruritus—Methotrexate—bone cancer	0.000394	0.00186	CcSEcCtD
Tapentadol—OPRM1—GPCR ligand binding—GRM4—bone cancer	0.000393	0.00385	CbGpPWpGaD
Tapentadol—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000389	0.00382	CbGpPWpGaD
Tapentadol—Hypersensitivity—Epirubicin—bone cancer	0.000384	0.00182	CcSEcCtD
Tapentadol—Urticaria—Doxorubicin—bone cancer	0.000383	0.00181	CcSEcCtD
Tapentadol—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000381	0.00374	CbGpPWpGaD
Tapentadol—Diarrhoea—Methotrexate—bone cancer	0.000381	0.0018	CcSEcCtD
Tapentadol—Asthenia—Epirubicin—bone cancer	0.000374	0.00177	CcSEcCtD
Tapentadol—Pruritus—Epirubicin—bone cancer	0.000369	0.00175	CcSEcCtD
Tapentadol—UGT1A9—Biological oxidations—GSTP1—bone cancer	0.000369	0.00362	CbGpPWpGaD
Tapentadol—Dizziness—Methotrexate—bone cancer	0.000368	0.00174	CcSEcCtD
Tapentadol—UGT1A9—Metapathway biotransformation—GSTP1—bone cancer	0.000364	0.00357	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—JUN—bone cancer	0.000361	0.00355	CbGpPWpGaD
Tapentadol—Diarrhoea—Epirubicin—bone cancer	0.000357	0.00169	CcSEcCtD
Tapentadol—Hypersensitivity—Doxorubicin—bone cancer	0.000355	0.00168	CcSEcCtD
Tapentadol—Vomiting—Methotrexate—bone cancer	0.000354	0.00168	CcSEcCtD
Tapentadol—Rash—Methotrexate—bone cancer	0.000351	0.00166	CcSEcCtD
Tapentadol—Dermatitis—Methotrexate—bone cancer	0.000351	0.00166	CcSEcCtD
Tapentadol—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000351	0.00344	CbGpPWpGaD
Tapentadol—Headache—Methotrexate—bone cancer	0.000349	0.00165	CcSEcCtD
Tapentadol—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000348	0.00341	CbGpPWpGaD
Tapentadol—Asthenia—Doxorubicin—bone cancer	0.000346	0.00164	CcSEcCtD
Tapentadol—Dizziness—Epirubicin—bone cancer	0.000345	0.00163	CcSEcCtD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000344	0.00338	CbGpPWpGaD
Tapentadol—Pruritus—Doxorubicin—bone cancer	0.000341	0.00161	CcSEcCtD
Tapentadol—OPRM1—GPCR ligand binding—GRM1—bone cancer	0.00034	0.00334	CbGpPWpGaD
Tapentadol—Vomiting—Epirubicin—bone cancer	0.000332	0.00157	CcSEcCtD
Tapentadol—Nausea—Methotrexate—bone cancer	0.000331	0.00157	CcSEcCtD
Tapentadol—Diarrhoea—Doxorubicin—bone cancer	0.00033	0.00156	CcSEcCtD
Tapentadol—Rash—Epirubicin—bone cancer	0.000329	0.00156	CcSEcCtD
Tapentadol—Dermatitis—Epirubicin—bone cancer	0.000328	0.00155	CcSEcCtD
Tapentadol—Headache—Epirubicin—bone cancer	0.000327	0.00155	CcSEcCtD
Tapentadol—OPRD1—GPCR ligand binding—SMO—bone cancer	0.000324	0.00318	CbGpPWpGaD
Tapentadol—Dizziness—Doxorubicin—bone cancer	0.000319	0.00151	CcSEcCtD
Tapentadol—UGT2B7—Metabolism—NDUFA12—bone cancer	0.000318	0.00312	CbGpPWpGaD
Tapentadol—Nausea—Epirubicin—bone cancer	0.00031	0.00147	CcSEcCtD
Tapentadol—Vomiting—Doxorubicin—bone cancer	0.000307	0.00145	CcSEcCtD
Tapentadol—Rash—Doxorubicin—bone cancer	0.000304	0.00144	CcSEcCtD
Tapentadol—Dermatitis—Doxorubicin—bone cancer	0.000304	0.00144	CcSEcCtD
Tapentadol—Headache—Doxorubicin—bone cancer	0.000302	0.00143	CcSEcCtD
Tapentadol—OPRD1—GPCR downstream signaling—GRM4—bone cancer	0.000299	0.00294	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—RGS1—bone cancer	0.000299	0.00294	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000297	0.00292	CbGpPWpGaD
Tapentadol—Nausea—Doxorubicin—bone cancer	0.000287	0.00136	CcSEcCtD
Tapentadol—SLC6A4—Circadian rythm related genes—CDK4—bone cancer	0.000286	0.0028	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—SMO—bone cancer	0.000284	0.00278	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—JUN—bone cancer	0.000283	0.00277	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—GRM4—bone cancer	0.000272	0.00267	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—RGS1—bone cancer	0.000272	0.00267	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—NT5C3A—bone cancer	0.000263	0.00259	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—GRM4—bone cancer	0.000262	0.00258	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—RGS1—bone cancer	0.000262	0.00258	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—GRM1—bone cancer	0.00026	0.00255	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NDUFA12—bone cancer	0.000258	0.00254	CbGpPWpGaD
Tapentadol—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000241	0.00237	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—SMO—bone cancer	0.00024	0.00235	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—GRM4—bone cancer	0.000238	0.00234	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—RGS1—bone cancer	0.000238	0.00234	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—GRM1—bone cancer	0.000236	0.00231	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—GRM1—bone cancer	0.000228	0.00223	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—JUN—bone cancer	0.000226	0.00221	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—RGS1—bone cancer	0.000222	0.00218	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—GRM4—bone cancer	0.000222	0.00218	CbGpPWpGaD
Tapentadol—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.00022	0.00216	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NT5C3A—bone cancer	0.000214	0.0021	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—GRM1—bone cancer	0.000207	0.00203	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000203	0.00199	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—GRM4—bone cancer	0.000201	0.00198	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—RGS1—bone cancer	0.000201	0.00198	CbGpPWpGaD
Tapentadol—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.0002	0.00196	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—GRM1—bone cancer	0.000192	0.00189	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000186	0.00183	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000185	0.00181	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—JUN—bone cancer	0.000184	0.00181	CbGpPWpGaD
Tapentadol—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000184	0.0018	CbGpPWpGaD
Tapentadol—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000182	0.00179	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—GRM1—bone cancer	0.000175	0.00171	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000173	0.0017	CbGpPWpGaD
Tapentadol—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.000171	0.00168	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—GNA11—bone cancer	0.000167	0.00164	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—SMO—bone cancer	0.000166	0.00163	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—GRM4—bone cancer	0.000161	0.00158	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RGS1—bone cancer	0.000161	0.00158	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000159	0.00156	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000158	0.00155	CbGpPWpGaD
Tapentadol—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000157	0.00154	CbGpPWpGaD
Tapentadol—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000156	0.00153	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—GNA11—bone cancer	0.000152	0.00149	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—IL3—bone cancer	0.000152	0.00149	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—GNA11—bone cancer	0.000147	0.00144	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—SMO—bone cancer	0.000146	0.00143	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—GRM4—bone cancer	0.000141	0.00138	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RGS1—bone cancer	0.000141	0.00138	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—GRM1—bone cancer	0.000139	0.00137	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL3—bone cancer	0.000138	0.00135	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—GNA11—bone cancer	0.000133	0.00131	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—IL3—bone cancer	0.000133	0.0013	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—GNA11—bone cancer	0.000124	0.00122	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—SMO—bone cancer	0.000123	0.00121	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—GRM1—bone cancer	0.000122	0.0012	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—TP53—bone cancer	0.000122	0.00119	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NDUFA12—bone cancer	0.000121	0.00119	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL3—bone cancer	0.000121	0.00118	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—GRM4—bone cancer	0.000119	0.00117	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RGS1—bone cancer	0.000119	0.00117	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ENO2—bone cancer	0.000115	0.00113	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—GNA11—bone cancer	0.000113	0.0011	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—IL3—bone cancer	0.000112	0.0011	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NDUFA12—bone cancer	0.000112	0.0011	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NDUFA12—bone cancer	0.000111	0.00109	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—DHFR—bone cancer	0.000107	0.00105	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—GRM1—bone cancer	0.000103	0.00101	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL3—bone cancer	0.000102	0.001	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NT5C3A—bone cancer	0.000101	0.000987	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GNA11—bone cancer	0.0001	0.000982	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SMO—bone cancer	9.81e-05	0.000963	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ENO2—bone cancer	9.38e-05	0.00092	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NT5C3A—bone cancer	9.25e-05	0.000908	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NT5C3A—bone cancer	9.17e-05	0.0009	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CYP3A4—bone cancer	9.07e-05	0.00089	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—GNA11—bone cancer	8.97e-05	0.00088	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—DHFR—bone cancer	8.7e-05	0.000854	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SMO—bone cancer	8.6e-05	0.000844	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ATF1—bone cancer	8.34e-05	0.000818	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL3—bone cancer	8.13e-05	0.000798	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GNA11—bone cancer	8.13e-05	0.000798	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—GNA11—bone cancer	7.87e-05	0.000772	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GSTP1—bone cancer	7.76e-05	0.000761	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CYP3A4—bone cancer	7.37e-05	0.000723	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.33e-05	0.00072	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ATF1—bone cancer	7.31e-05	0.000718	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SMO—bone cancer	7.27e-05	0.000713	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL3—bone cancer	7.13e-05	0.0007	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TGFBR2—bone cancer	6.96e-05	0.000683	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—GNA11—bone cancer	6.65e-05	0.000652	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IGF1R—bone cancer	6.54e-05	0.000642	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSTP1—bone cancer	6.3e-05	0.000619	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ATF1—bone cancer	6.18e-05	0.000607	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TGFBR2—bone cancer	6.1e-05	0.000599	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL3—bone cancer	6.03e-05	0.000591	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IGF1R—bone cancer	5.74e-05	0.000563	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TGFBR2—bone cancer	5.15e-05	0.000506	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IGF1R—bone cancer	4.85e-05	0.000476	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KIT—bone cancer	4.75e-05	0.000466	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—BRAF—bone cancer	4.46e-05	0.000438	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ENO2—bone cancer	4.41e-05	0.000433	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—EGFR—bone cancer	4.32e-05	0.000424	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KIT—bone cancer	4.16e-05	0.000408	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—DHFR—bone cancer	4.09e-05	0.000401	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ENO2—bone cancer	4.05e-05	0.000398	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTGS2—bone cancer	4.02e-05	0.000394	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ENO2—bone cancer	4.02e-05	0.000394	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—BRAF—bone cancer	3.91e-05	0.000384	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GNA11—bone cancer	3.82e-05	0.000375	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—EGFR—bone cancer	3.79e-05	0.000372	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—DHFR—bone cancer	3.76e-05	0.000369	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MDM2—bone cancer	3.74e-05	0.000367	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—DHFR—bone cancer	3.73e-05	0.000366	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KIT—bone cancer	3.52e-05	0.000345	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GNA11—bone cancer	3.51e-05	0.000345	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GNA11—bone cancer	3.48e-05	0.000342	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP3A4—bone cancer	3.46e-05	0.00034	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.45e-05	0.000338	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—BRAF—bone cancer	3.31e-05	0.000324	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MDM2—bone cancer	3.28e-05	0.000322	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—bone cancer	3.27e-05	0.000321	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—JUN—bone cancer	3.25e-05	0.000319	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—EGFR—bone cancer	3.2e-05	0.000314	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP3A4—bone cancer	3.19e-05	0.000313	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MMP9—bone cancer	3.16e-05	0.00031	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP3A4—bone cancer	3.16e-05	0.00031	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.14e-05	0.000308	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTP1—bone cancer	2.96e-05	0.000291	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—JUN—bone cancer	2.85e-05	0.00028	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MMP9—bone cancer	2.77e-05	0.000272	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MDM2—bone cancer	2.77e-05	0.000272	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTP1—bone cancer	2.73e-05	0.000267	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTP1—bone cancer	2.7e-05	0.000265	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EGFR—bone cancer	2.55e-05	0.000251	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—JUN—bone cancer	2.41e-05	0.000236	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP9—bone cancer	2.34e-05	0.00023	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGFR—bone cancer	2.24e-05	0.00022	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—bone cancer	2.14e-05	0.00021	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGFR—bone cancer	1.89e-05	0.000186	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—bone cancer	1.88e-05	0.000185	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—bone cancer	1.59e-05	0.000156	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—bone cancer	1.54e-05	0.000151	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—bone cancer	1.41e-05	0.000139	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—bone cancer	1.4e-05	0.000137	CbGpPWpGaD
